Literature DB >> 17565745

Human papillomavirus triage of women with persistent borderline or mildly dyskaryotic smears: Comparison of costs and side effects of three alternative strategies.

Matejka Rebolj1, Aagje G Bais, Marjolein van Ballegooijen, Rob Boer, Willem-Jan Meerding, Theo J M Helmerhorst, J Dik F Habbema.   

Abstract

The conventional direct referral to colposcopy of persistent borderline or mildly dyskaryotic (BMD) smears in cervical cancer screening leads to considerable unnecessary referrals and associated anxiety and costs. This may be improved by including testing for oncogenic human papillomavirus (HPV) in the triage. We assessed costs and side effects (referrals, treatments and time in follow-up) for 3 possible HPV triage strategies (immediate HPV testing, a 6-month delay in HPV testing, a 2-stage combination of both) and compared them with the conventional strategy. The assessments are based on recent Dutch data from various national databases and trials. We estimated that the referral rate could be reduced by 49, 58 and 58% with immediate, delayed and 2-stage HPV testing, respectively. As a consequence, the average length of follow-up, as well as average costs, also decrease. Therefore, we advocate including HPV testing before referring to colposcopy. Among the 3 HPV strategies, analysis of additional aspects favors implementation of immediate HPV testing.

Entities:  

Mesh:

Year:  2007        PMID: 17565745     DOI: 10.1002/ijc.22838

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

Review 1.  Primary HPV screening for cervical cancer prevention: results from European trials.

Authors:  Elsebeth Lynge; Matejka Rebolj
Journal:  Nat Rev Clin Oncol       Date:  2009-11-10       Impact factor: 66.675

2.  Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing.

Authors:  J van Rosmalen; I M C M de Kok; M van Ballegooijen
Journal:  BJOG       Date:  2012-01-18       Impact factor: 6.531

3.  Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model.

Authors:  Inge M C M de Kok; Joost van Rosmalen; Joakim Dillner; Marc Arbyn; Peter Sasieni; Thomas Iftner; Marjolein van Ballegooijen
Journal:  BMJ       Date:  2012-03-05

4.  High lifetime probability of screen-detected cervical abnormalities.

Authors:  Maiju Pankakoski; Sirpa Heinävaara; Tytti Sarkeala; Ahti Anttila
Journal:  J Med Screen       Date:  2017-01-10       Impact factor: 2.136

5.  Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: population based cohort study.

Authors:  Matejka Rebolj; Theo Helmerhorst; Dik Habbema; Caspar Looman; Rob Boer; Joost van Rosmalen; Marjolein van Ballegooijen
Journal:  BMJ       Date:  2012-10-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.